Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients

Journal of Neuroimmunology

Volumn 235, Issue 1-2, 2011, Pages 70-76

  Skarica, Mario ^a   Eckstein, Christopher ^a   Whartenby, Katharine A ^a   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cytokines; Immunomodulation; Multiple sclerosis; Natalizumab; PML

Indexed keywords

CD14 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CYTOKINE; NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL COMPOSITION; CELL COUNT; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 79957973246     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.02.010     Document Type: Article

References (30)

1. Alter A., Duddy M., Hebert S., Biernacki K., Prat A., Antel J.P., Yong V.W., Nuttall R.K., Pennington C.J., Edwards D.R., Bar-Or A. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 2003, 170:4497-4505.
2. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. 2001, 167:1245-1253.
3. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., Pennington C.J., Bourgoin P., Edwards D.R., Yong V.W. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
4. Bauer M., Brakebusch C., Coisne C., Sixt M., Wekerle H., Engelhardt B., Fassler R. Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl Acad. Sci. USA 2009, 106:1920-1925.
5. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., Martin R. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 2006, 103:5941-5946.
6. Bonig H., Wundes A., Chang K.H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008, 111:3439-3441.
7. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., Laubach J., Bawn S.D., Gordon L.I., Winter J.N., Furman R.R., Vose J.M., Zelenetz A.D., Mamtani R., Raisch D.W., Dorshimer G.W., Rosen S.T., Muro K., Gottardi-Littell N.R., Talley R.L., Sartor O., Green D., Major E.O., Bennett C.L. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
8. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151.
9. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J. Immunol. 2004, 172:3422-3427.
10. Fleming J.C., Bao F., Chen Y., Hamilton E.F., Relton J.K., Weaver L.C. Alpha4beta1 integrin blockade after spinal cord injury decreases damage and improves neurological function. Exp. Neurol. 2008, 214:147-159.
11. Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L.L., Berman, M., Zein, F., Wilson, E., Yednock, T., Sandrock, A., Goelz, S.E., Subramanyam, M., 2010. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68, 295-303.
12. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
13. Iwata, Y., Matsushita, T., Horikawa, M., Dilillo, D.J., Yanaba, K., Venturi, G.M., Szabolcs, P.M., Bernstein, S.H., Magro, C.M., Williams, A.D., Hall, R.P., St Clair, E.W., Tedder, T.F., 2010. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530-541.
14. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005, 353:369-374.
15. Krumbholz M., Meinl I., Kumpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008, 71:1350-1354.
16. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353:375-381.
17. Major E.O. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N. Engl. J. Med. 2009, 361:1041-1043.
18. Niino M., Bodner C., Simard M.L., Alatab S., Gano D., Kim H.J., Trigueiro M., Racicot D., Guerette C., Antel J.P., Fournier A., Grand'Maison F., Bar-Or A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 2006, 59:748-754.
19. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
20. Ransohoff R.M. Natalizumab for multiple sclerosis. N. Engl. J. Med. 2007, 356:2622-2629.
21. Ransohoff, R.M., 2010. PML risk and natalizumab: more questions than answers. Lancet Neurol 9, 231-233.
22. Rice G.P., Hartung H.P., Calabresi P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 64:1336-1342.
23. Sabath B.F., Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J. Infect. Dis. 2002, 186(Suppl 2):S180-S186.
24. Scott L.M., Priestley G.V., Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol. Cell. Biol. 2003, 23:9349-9360.
25. Silvy A., Altevogt P., Mondiere P., Bella C., Defrance T. A role for the VLA-4 integrin in the activation of human memory B cells. Eur. J. Immunol. 1997, 27:2757-2764.
26. Stenner M.P., Waschbisch A., Buck D., Doerck S., Einsele H., Toyka K.V., Wiendl H. Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS ONE 2008, 3:e3319.
27. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006, 59:743-747.
28. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 2005, 353:362-368.
29. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
30. Zheng J., Liu Y., Qin G., Chan P.L., Mao H., Lam K.T., Lewis D.B., Lau Y.L., Tu W. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells. J. Immunol. 2009, 183:3742-3750.